Lavina Ahmed

BerGenBio (Norway) — Norway

Immunology and Microbiology · Life Sciences

7h-index182citations12works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Phagocytosis and Immune Regulation(11), Pancreatic and Hepatic Oncology Research(9), Cancer Immunotherapy and Biomarkers(5), Renal and related cancers(3), Liver physiology and pathology(2)

Publications12 total

<scp>AXL</scp> targeting reduces fibrosis development in experimental unilateral ureteral obstruction
Physiological Reports·2019· 23 citedOpen Access
Combination of bemcentinib (BGB324): A first-in-class selective oral AXL inhibitor, with pembrolizumab in patients with triple negative breast cancer and adenocarcinoma of the lung.
Journal of Clinical Oncology·2018· 19 cited
Abstract 626: BGB324, a selective small molecule inhibitor of receptor tyrosine kinase AXL, abrogates tumor intrinsic and microenvironmental immune suppression and enhances immune checkpoint inhibitor efficacy in lung and mammary adenocarcinoma models
Cancer Research·2017· 7 cited
Clear Cell Renal Cell Carcinoma is linked to Epithelial-to-Mesenchymal Transition and to Fibrosis
Physiological Reports·2017· 41 citedOpen Access
Abstract B027: BGB324, a selective small molecule inhibitor of AXL receptor tyrosine kinase, enhances immune checkpoint inhibitor efficacy
Cancer Immunology Research·2016· 1 cited
Abstract 566: BGB324, a selective small molecule inhibitor of the receptor tyrosine kinase AXL, enhances immune checkpoint inhibitor efficacy
Cancer Research·2016· 5 cited
Novel anti-human Axl monoclonal antibodies for improved patient biomarker studies
Verein zur Förderung des biologisch technologischen Fortschritts in der Medizin e.V.·2016· 4 citedOpen Access
Strong Expression of Hypoxia-Inducible Factor-1α (HIF-1α) Is Associated with Axl Expression and Features of Aggressive Tumors in African Breast Cancer
PLoS ONE·2016· 48 citedOpen Access
Abstract B014: BGB324, a selective small molecule inhibitor of the receptor tyrosine kinase AXL, enhances immune checkpoint inhibitor efficacy
Cancer Immunology Research·2016· 2 cited
Increased tumor cell expression of Axl is a marker of aggressive features in breast cancer among African women
Apmis·2015· 13 cited
Abstract 1747: BGB324, a selective small molecule Axl kinase inhibitor to overcome EMT-associated drug resistance in carcinomas: Therapeutic rationale and early clinical studies
Cancer Research·2014· 15 cited
Abstract B30: Selective small molecule AXL inhibitor BGB324 overcomes acquired drug resistance in non-small cell lung carcinoma models.
Clinical Cancer Research·2014· 4 cited

Frequent Co-authors

James B. Lorens(10), Gro Gausdal(9), Rolf A. Brekken(7), Katarzyna Wnuk-Lipińska(7), Magnus Blø(6), Kjersti Davidsen(5), Linn Hodneland(5), Agnete S. T. Engelsen(4), Sébastien Bougnaud(4), Monica Hellesøy(4), Hallvard Haugen(4), David Micklem(4), Hawa Nalwoga(3), Lars A. Akslen(3), Maria Lie(3), Kristina Y. Aguilera(3), Anna Boniecka(3), Salem Chouaı̈b(3), Oddbjørn Straume(3), Sergej M. Kiprijanov(3)